Urihk Pharmaceutical Private Limited, a active foreign private limited company, was established on 08 December 2017 in Mumbai, Maharashtra, India. Engaging in pharmaceutical retailers & distributors within the trade sector, it holds CIN: U51909MH2017FTC302652. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹30.00 Cr and a paid-up capital of ₹19.82 Cr.
It upholds a compliant status. Employing 79 professional, Its leadership includes Rajesh Madanlal Gupta (Whole-Time Director), Tarun Gupta (Director), Rajesh Sharma (Director). Past directors included Rajesh Sharma, Xuekui Chen, Xinpei Yu. Its latest AGM occurred on 30 September 2025, with the balance sheet filed on 31 March 2025. It is based at Office No. 602-603, Sai Samarth Business Park, Near Wasan Motors, Deonar, Govandi (East, ),, Mumbai, Maharashtra, 400088.
U51909MH2017FTC302652
302652
08 December 2017
₹30.00 Cr
₹19.82 Cr
Roc Mumbai
Unlisted
Active
Explore comprehensive insights into Urihk Pharmaceutical Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rajesh Madanlal Gupta | Whole-Time Director | 08 Dec 2017 | Current |
| Tarun Gupta | Director | 08 Dec 2017 | Current |
| Rajesh Sharma | Director | 01 Jan 2020 | Current |
| Xuekui Chen | Director | 13 Apr 2018 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 09 Nov 2020 | Past |
| Pramod Abcsdd | Additional Director | 29 Sep 2018 | Past |
| Pramod Abcsdd | Additional Director | 29 Sep 2018 | Past |
| Pramod Abcsdd | Company Secretary | 05 Sep 2019 | Past |
| Pramod Abcsdd | Company Secretary | - | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Urihk Pharmaceutical Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 73.25% decrease. The company also saw a substantial fall in profitability, with a 41.83% decrease in profit. The company's net worth observed a substantial decline by a decrease of 225.43%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Urihk Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Urihk Pharmaceutical has a workforce of 79 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Urihk Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Urihk Pharmaceutical's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Urihk Pharmaceutical Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records. was completed.
Urihk Pharmaceutical Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai. was recorded as a recent event.
Progress on Hema Bhagtani was appointed as a Company Secretary was appointed as a Company Secretary on 27 Mar 2025 & has been associated with this company since 8 months 4 days . was documented.
Progress on Rajesh Sharma was appointed as a Director was appointed as a Director on 01 Jan 2020 & has been associated with this company since 5 years 10 months . was documented.
Progress on Xuekui Chen was appointed as a Director was appointed as a Director on 13 Apr 2018 & has been associated with this company since 7 years 7 months . was documented.
The activity Rajesh Madanlal Gupta was appointed as a Whole-time director was appointed as a Whole-time director on 08 Dec 2017 & has been associated with this company since 7 years 11 months . was completed.
The CIN of Urihk Pharmaceutical Private Limited is U51909MH2017FTC302652.
Urihk Pharmaceutical Private Limited is headquartered at Office No. 602-603, Sai Samarth Business Park, Near Wasan Motors, Deonar, Govandi (East, ),, Mumbai, Maharashtra, 400088.
Urihk Pharmaceutical Private Limited was incorporated on 08 December 2017.
The current directors of Urihk Pharmaceutical Private Limited are
The primary industry of Urihk Pharmaceutical Private Limited is Trade.
Urihk Pharmaceutical Private Limited is unlisted.
The authorized capital of Urihk Pharmaceutical Private Limited is ₹30.00 Cr, and the paid-up capital is ₹19.82 Cr.
The compliance status of Urihk Pharmaceutical Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX